An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma
一项探索性、开放标签、随机、多中心研究,旨在研究糖基化抗体(imgatuzumab)和西妥昔单抗在可手术头颈部鳞状细胞癌患者中的药效学。
期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdx489
Temam, S; Spicer, J; Farzaneh, F; Soria, J C; Oppenheim, D; McGurk, M; Hollebecque, A; Sarini, J; Hussain, K; Soehrman Brossard, S; Manenti, L; Evers, S; Delmar, P; Di Scala, L; Mancao, C; Feuerhake, F; Andries, L; Ott, M G; Passioukov, A; Delord, J P